Results 101 to 110 of about 63,852 (318)
Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites [PDF]
, 1991 Wladimiro Jiménez +5 more
openalex +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul +13 more
wiley +1 more source
ANTIDIURESIS DURING PEEP IS HOT MEDIATED BY AN INHIBITION OF ATRIAL NATRIURETIC FACTOR RELEASE [PDF]
, 1988 M D Fratacci +6 more
openalex +1 more source
The atrial natriuretic factor. [PDF]
Heart, 1986 In less than three years since the rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats was reported the factor responsible for the diuretic, natriuretic, and vasodilating activity of the atrial homogenates was isolated, its chemical structure elucidated, and its total synthesis achieved. Also the cDNA and
openaire +2 more sources
Splanchnic Removal of Atrial Natriuretic Factor (ANF) in Man [PDF]
, 1990 In order to assess the effect of food ingestion on splanchnic disposal of human alpha-atrial natriuretic peptide (ANF), hepatic-intestinal removal of ANF was determined before and after a test meal.
Bendtsen, Flemming +2 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao +27 more
wiley +1 more source
Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022
ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié +5 more
wiley +1 more source
Sudden cardiac death in patients with ischemic heart failure undergoing coronary artery bypass grafting results from the STICH randomized clinical trial (Surgical Treatment for Ischemic Heart Failure) [PDF]
, 2017 Background—The risk of sudden cardiac death (SCD) in patients with heart failure following CABG has not been examined in a contemporary clinical trial of surgical revascularization. This analysis describes the incidence, timing and clinical predictors of
Al-Khatib, Sana M. +19 more
core +2 more sources
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source